Clinical Trials Sponsored by Inovio Pharmaceuticals

Total 21254 results

Inovio Pharmaceuticals

Completed

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Respiratory Papillomatosis

United States
Inovio Pharmaceuticals

Completed

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (REVEAL 1)

Cervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSIL

United States, Spain, Portugal, Italy, Philippines, Thailand, Slovakia, Lithuania, Estonia, Belgium, South Africa, Germany, Argentina, United Kingdom, Poland, Puerto Rico, Finland, Mexico, Peru
Inovio Pharmaceuticals

Active, not recruiting

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Urothelial Carcinoma

United States, Spain
Inovio Pharmaceuticals

Active, not recruiting

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Glioblastoma

United States
Inovio Pharmaceuticals

Withdrawn

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

Coronavirus Infection
Inovio Pharmaceuticals

Completed

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Cervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSIL

United States, Spain, Lithuania, Estonia, South Africa, Argentina, Brazil, Finland, Poland, Puerto Rico
Inovio Pharmaceuticals

Completed

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Papillomavirus Infections

United States, Puerto Rico
Inovio Pharmaceuticals

Completed

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Human Papillomavirus (HPV) | Vulvar Dysplasia | Vulvar Intraepithelial Neoplasia (VIN) | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | VIN2 | VIN3 | Pre-cancerous Lesions of the Vulva

United States
Inovio Pharmaceuticals

Completed

A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

Cervical Cancer

United States
Inovio Pharmaceuticals

Completed

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

Human Papillomavirus (HPV)

Puerto Rico, United States
Inovio Pharmaceuticals

Completed

Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer

Head and Neck Cancer

United States
Inovio Pharmaceuticals

Completed

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

Healthy

United States
Inovio Pharmaceuticals

Completed

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Anal Neoplasm

United States, Canada
Inovio Pharmaceuticals

Terminated

Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Inovio Pharmaceuticals

Terminated

Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma

Head Neck Cancer

United States
Inovio Pharmaceuticals

Completed

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

Hepatitis B

Australia, Taiwan, United States, Singapore, New Zealand, Hong Kong, Thailand, Philippines
Inovio Pharmaceuticals

Completed

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (HPV-003)

Cervical Intraepithelial Neoplasia

South Africa, United States, Korea, Republic of, Canada, Estonia, India, Georgia, Australia, Puerto Rico
Inovio Pharmaceuticals

Completed

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Prostate Cancer

United States
Inovio Pharmaceuticals

Completed

Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer

Cancer

United States
Inovio Pharmaceuticals

Completed

A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001

Healthy

United States
Inovio Pharmaceuticals

Completed

A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

Healthy

United States
Inovio Pharmaceuticals

Completed

Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants (HIV-001)

HIV Infections | HIV-1 Infection

United States
Tripep AB
Inovio Pharmaceuticals

Unknown

Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients

Chronic Hepatitis C Virus Infection

Sweden
University of Pennsylvania
Inovio Pharmaceuticals

Recruiting

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

BRCA1/2 Mutation

United States
Inovio Pharmaceuticals
University of Pennsylvania

Completed

Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies

Aerodigestive Precancerous Lesions and Malignancies

United States
University of Pennsylvania
Inovio Pharmaceuticals

Completed

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

Healthy Volunteers

United States
Inovio Pharmaceuticals
University of Pennsylvania

Completed

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Cancer

United States
University of Manitoba
Inovio Pharmaceuticals

Completed

DNA-based Influenza Vaccine in the Elderly

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza, Human | Orthomyxoviridae Infections

Canada
ChronTech Pharma AB
Inovio Pharmaceuticals

Unknown

CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects

Chronic Hepatitis C

Sweden
GeneOne Life Science, Inc.
Inovio Pharmaceuticals

Completed

Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males

Healthy

Korea, Republic of
National Cancer Institute (NCI)
Inovio Pharmaceuticals

Active, not recruiting

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Hepatitis C Infection | Chronic Hepatitis

United States, Puerto Rico
GeneOne Life Science, Inc.
Inovio Pharmaceuticals

Completed

GLS-5700 in Dengue Virus Seropositive Adults

Healthy | Zika

Puerto Rico
GeneOne Life Science, Inc.
Inovio Pharmaceuticals

Completed

GLS-5700 in Healthy Volunteers

Healthy

United States, Canada
GeneOne Life Science, Inc.
Inovio Pharmaceuticals

Completed

Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection

HCV Infection

Korea, Republic of
GeneOne Life Science, Inc.
Inovio Pharmaceuticals

Completed

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (VGX-6150-01)

Hepatitis C, Chronic

Korea, Republic of
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Lebanon, Jordan, Kenya
Inovio Pharmaceuticals
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Terminated

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Infection | COVID-19 Disease

United States, Mexico, Colombia
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

Lassa Fever

United States
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

Lassa Fever

Ghana
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

Coronavirus Infection

United States
GeneOne Life Science, Inc.
International Vaccine Institute; Inovio Pharmaceuticals

Completed

Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers

Healthy

Korea, Republic of
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
International Vaccine Institute
Inovio Pharmaceuticals; Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

Coronavirus Infection | SARS-CoV 2

Korea, Republic of
Inovio Pharmaceuticals
GeneOne Life Science, Inc.; Defense Advanced Research Projects Agency

Completed

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Ebola Vaccine

United States
Inova Health Care Services
Novartis Pharmaceuticals

Completed

New Individualized Therapy Trial for Metastatic Colorectal Cancer (NITMEC)

Colorectal Cancer | Colorectal Neoplasm

United States
Merck Sharp & Dohme LLC
University of California, San Diego; Inovio Pharmaceuticals

Completed

A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)

Healthy
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment

Clinical Trials Sponsored by Inovio Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations